AOA Dx, Inc.

Cover Block

PUBLIC

Attribute	Value
Name	AOA Dx, Inc.
Tagline	Developing blood-based tests for early cancer detection, with an initial focus on ovarian cancer.
Headquarters	Denver, US
Founded	2020
Stage	Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$9,500,000)

Links

PUBLIC

• Website: https://aoadx.com
• LinkedIn: https://www.linkedin.com/company/aoa-dx-inc

Executive Summary

PUBLIC

AOA Dx is developing a blood-based test to detect ovarian cancer earlier than current methods, a clinical challenge where improved diagnostics could directly impact mortality rates and healthcare costs [StartupIntros]. Founded in 2020, the company's initial product, AKRIVIS GD™, is a multi-omics liquid biopsy that analyzes tumor-derived gangliosides, a class of biomarkers the company positions as novel compared to established protein-based approaches [YouTube]. The founding team, led by CEO Oriana Papin-Zoghbi, brings experience in medical technology development, though detailed prior professional histories are not extensively documented in public sources [Overlooked Podcast]. To date, the company has secured at least $9.5 million in disclosed seed and venture equity funding from a syndicate that includes Joyance Partners, AlleyCorp, and Y Combinator, with a subsequent $17 million Series A reported in late 2023 [StartupIntros], [Crunchbase, 2026]. The business model targets diagnostic laboratories and healthcare payers, but commercial traction remains pre-revenue as the company advances clinical validation. Over the next 12-18 months, the critical milestones to watch are the publication of robust clinical validation data for its lead test and progress toward securing regulatory clearances, which will determine its path to market adoption.

Data Accuracy: GREEN -- Company claims and funding details corroborated by multiple independent sources.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$9,500,000)

Company Overview

PUBLIC

AOA Dx, Inc. was founded in 2020, a Denver-based entity focused on developing blood-based diagnostics for early cancer detection [Crunchbase]. The company's initial focus on ovarian cancer emerged from a recognized clinical gap in accurate, non-invasive early detection methods, a problem the founding team sought to address with a novel biomarker approach [StartupIntros].

Key corporate milestones follow a typical biotech development path. The company completed the Y Combinator accelerator program in the winter 2021 batch, securing initial venture backing [Y Combinator]. A $2.5 million seed round led by Joyance Partners closed in June 2021, followed by a $7.0 million venture equity round in September 2022 [StartupIntros]. The company announced a $17 million Series A financing in October 2023, led by Good Growth Capital with participation from LongeVC, bringing its total publicly disclosed funding to at least $26.5 million [Crunchbase, 2026], [LongeVC, 2026].

Data Accuracy: GREEN -- Confirmed by Crunchbase, Y Combinator, and investor announcements.

Product and Technology

MIXED AOA Dx's core proposition rests on a specific, proprietary biomarker class and a multi-omics analysis engine, a combination designed to address a known diagnostic gap. The company's lead product, AKRIVIS GD™, is a blood-based liquid biopsy test intended for the early detection of ovarian cancer in symptomatic women [StartupIntros]. The technical differentiation is centered on the use of tumor marker gangliosides, a type of glycolipid, which the company positions as a novel biomarker class compared to more established protein-based assays [YouTube][Dealroom]. This approach is powered by the GlycoLocate™ platform, an AI-enabled system that analyzes these gangliosides alongside proteins and other molecular signals in a multi-omics framework [AOA Dx][CB Insights].

The company has made specific performance claims for its technology in public materials. According to the company's website, its multi-omic model achieved 94.8% sensitivity for early-stage ovarian cancer and 94.4% across all stages and subtypes [AOA Dx]. In a separate claim, the company states the AKRIVIS GD™ test, incorporating a novel panel of tumor gangliosides and a proprietary algorithm, achieved an area under the curve (AUC) of 0.969 for detecting ovarian cancer in early stages [AOA Dx]. The platform is described as non-invasive and designed to integrate into clinical workflows for gynecologic oncologists and diagnostic labs [StartupIntros].

Data Accuracy: YELLOW -- Product claims are sourced primarily from company materials; performance metrics are not yet independently validated in peer-reviewed literature.

Market Research

PUBLIC

The urgency for better ovarian cancer diagnostics is underscored by a clinical reality where late-stage detection remains the norm, driving both patient mortality and systemic cost burdens.

Third-party market sizing for early-stage ovarian cancer diagnostics specifically is not publicly available in the cited research. However, analogous markets provide a sense of scale. The global liquid biopsy market, a key enabling technology, was valued at approximately $13.2 billion in 2023 and is projected to reach $37.7 billion by 2030, growing at a compound annual rate of 16.2% [Grand View Research]. The broader women's health diagnostics market is similarly expansive, with some analyses estimating it could exceed $50 billion by 2030 [Precedence Research]. These figures suggest the addressable market for a successful test is substantial, though AOA Dx's initial serviceable obtainable market (SOM) would be a fraction of this, limited to symptomatic women presenting for evaluation in specific geographies.

Demand drivers are well-documented and multifaceted. The primary clinical tailwind is the stark survival gap: the five-year survival rate for ovarian cancer drops from over 90% when diagnosed at Stage I to below 30% when diagnosed at Stage III or IV [American Cancer Society]. This creates a powerful incentive for health systems and payers to adopt tools that shift diagnoses earlier, potentially reducing high-cost late-stage interventions. A secondary driver is the growing focus and investment in women's health, a historically underfunded segment that is now attracting significant venture capital and strategic interest [Rock Health].

Regulatory and reimbursement pathways represent the most significant macro forces. Gaining FDA approval or clearance is a non-negotiable hurdle for any diagnostic aiming for widespread clinical use in the United States. Beyond approval, securing reimbursement from Medicare and private payers is equally critical for commercial adoption. The process is lengthy, costly, and uncertain, often requiring the generation of robust clinical utility and health-economic data. Success in adjacent markets, such as multi-cancer early detection (MCED) tests, has demonstrated that navigating this landscape is possible but remains a formidable barrier for pre-commercial companies.

Data Accuracy: YELLOW -- Market sizing is based on analogous, broader markets from third-party reports; specific ovarian cancer diagnostic TAM is not confirmed.

Competitive Landscape

MIXED AOA Dx enters a diagnostic arena where the competitive advantage is defined by biomarker novelty and clinical validation, not just technical capability.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
AOA Dx	Blood-based, multi-omic liquid biopsy for early ovarian cancer detection.	Seed/Series A; >$26M total (estimated).	Proprietary glycolipid (ganglioside) biomarkers, AI-enabled GlycoLocate™ platform.	[StartupIntros], [Crunchbase, 2026]
Mercy BioAnalytics	Liquid biopsy for early cancer detection using extracellular vesicle (EV) analysis.	Venture stage; $96M total funding.	Focus on tumor-derived extracellular vesicles (tdEVs) as a biomarker source.	[Crunchbase]
Dxcover	Blood test for early detection of multiple cancers using infrared spectroscopy and AI.	Venture stage; ~$20M total funding.	Platform approach using metabolic fingerprinting via infrared light, not specific biomarkers.	[Crunchbase]

The competitive map for early cancer detection, particularly in ovarian cancer, is stratified by technological approach. Incumbent standard-of-care, primarily the CA-125 blood test and transvaginal ultrasound, are widely available but suffer from well-documented limitations in sensitivity and specificity for early-stage disease [Forbes, 2021]. The new wave of challengers, like AOA Dx, Mercy BioAnalytics, and Dxcover, are all developing liquid biopsies but are pursuing distinct biological signals. Mercy BioAnalytics analyzes extracellular vesicles, while Dxcover employs a spectroscopic technique to generate a metabolic fingerprint. AOA Dx’s specific wedge is its focus on gangliosides, a class of glycolipids it positions as a novel biomarker class compared to the protein-based assays that dominate the current landscape [YouTube]. Adjacent substitutes include comprehensive genomic profiling tests from larger oncology players, but these are often used in later-stage disease or for therapy selection rather than primary early detection.

AOA Dx’s defensible edge today rests on its proprietary biomarker panel and the associated algorithm. The company’s published data claims its multi-omic model achieved 94.8% sensitivity in early-stage ovarian cancer and an AUC of 0.969 [AOA DX, 2026]. This early technical validation, if replicated in larger studies, forms an initial data moat. The edge is perishable, however, as it is contingent on maintaining a lead in clinical study results and securing intellectual property around its specific ganglioside signatures. The company’s capital base, strengthened by its 2023 Series A, provides runway for continued R&D but is not uniquely large in a field where competitors have also raised significant sums.

The company’s most significant exposure is to competitors with broader platform ambitions or more advanced commercial pipelines. Mercy BioAnalytics, with nearly $100 million in funding, may have greater resources to accelerate clinical trials and pursue regulatory pathways for multiple cancers. Dxcover’s spectroscopic platform is inherently agnostic to cancer type, which could allow faster expansion beyond ovarian cancer. AOA Dx’s focused approach is a strength for depth but an exposure to breadth; if the ovarian cancer diagnostic market proves slower to adopt than a multi-cancer early detection (MCED) market, the company could be outflanked. Furthermore, it does not own the clinical channel or payer relationships, which will be critical for adoption and reimbursement.

The most plausible 18-month scenario hinges on clinical and regulatory milestones. The winner will likely be the first to secure a key regulatory designation, such as FDA Breakthrough Device status for ovarian cancer, or to publish compelling prospective clinical validation data in a major journal. If AOA Dx can achieve this while maintaining its reported accuracy metrics, it would solidify its position as the leader in glycolipid-based diagnostics for this specific indication. The loser in this period would be any player whose next-phase clinical data fails to meet expectations, leading to a dilution of investor confidence and a slowdown in development momentum. For AOA Dx, the risk is that a competitor’s alternative biomarker or platform technology demonstrates superior real-world performance in a head-to-head study, challenging the durability of its glycolipid thesis.

Data Accuracy: YELLOW -- Competitor details are confirmed via Crunchbase; AOA Dx's differentiation claims are sourced from company materials and investor profiles, requiring independent clinical corroboration.

Opportunity

PUBLIC

The prize for a successful, clinically validated early detection test for ovarian cancer is measured in thousands of lives saved annually and billions in healthcare cost avoidance, a commercial opportunity that could support a multi-billion dollar enterprise value for the category leader.

The headline opportunity for AOA Dx is to become the standard-of-care diagnostic for early-stage ovarian cancer, a disease where late detection is the norm and mortality remains stubbornly high. The company's path to this outcome rests on its specific technological claim: that its focus on gangliosides, a class of glycolipid biomarkers, offers a meaningful accuracy improvement over existing protein-based tests, particularly for early-stage disease. The company's own published data, while requiring independent validation, asserts a 94.8% sensitivity for early-stage ovarian cancer and an ability to detect 53% more early-stage patients than the current standard of care [AOA DX, 2026]. If these performance metrics hold in broader clinical trials and translate into regulatory approval and reimbursement, the AKRIVIS GD test could redefine the diagnostic pathway for symptomatic women, moving from a reliance on imaging and invasive procedures to a definitive blood test.

Multiple, concrete growth scenarios exist beyond the initial diagnostic application. The underlying GlycoLocate platform, designed to analyze gangliosides across cancer types, suggests a path to expanding the company's market reach significantly.

Scenario	What happens	Catalyst	Why it's plausible
Platform Expansion into Pan-Cancer Detection	The GlycoLocate biomarker panel and AI algorithm are validated for additional high-mortality cancers with poor early detection rates (e.g., pancreatic, liver).	Publication of a multi-cancer validation study or a strategic partnership with a large pharma company for companion diagnostics.	The company explicitly frames GlycoLocate as a platform for early-stage cancer detection, not a single-asset company [Dealroom]. Its AI-enabled, multi-omics approach is structurally built to incorporate new biomarker signatures.
Integration as a Reflex Test in Primary Care	The test is adopted by major clinical lab networks (e.g., Labcorp, Quest) as a reflex test for women presenting with abdominal symptoms, creating a high-volume screening funnel.	A partnership with a national laboratory, potentially an existing investor like Labcorp Venture Fund, to commercialize and distribute the test.	The test is designed for symptomatic women, fitting directly into existing clinical workflows for vague abdominal complaints [StartupIntros, Forbes, 2021]. Labcorp's strategic investment indicates commercial interest at the highest level [StartupIntros].

Compounding for AOA Dx would manifest as a clinical data moat that accelerates both regulatory progress and test performance. Each clinical sample processed not only generates revenue but also feeds the proprietary algorithm, theoretically improving its accuracy and broadening its applicability. This creates a reinforcing cycle: better performance drives higher clinician adoption and payer reimbursement, which in turn generates more samples and data. Early signals of this flywheel are not yet public, as the company appears pre-commercial, but the AI-enabled nature of the platform is built to capitalize on scale [CB Insights, 2026]. Success with the first indication would also de-risk expansion into other cancers, as the core regulatory and commercial playbook would be established.

The size of the win is anchored by the valuation of commercial-stage diagnostics companies. Grail, a leader in multi-cancer early detection blood tests, was acquired by Illumina for $8 billion in 2021. While Grail's pan-cancer scope is broader, it illustrates the premium placed on paradigm-shifting liquid biopsy platforms. A more direct, though still aspirational, comparable could be the standalone value of a successful single-cancer diagnostic with blockbuster potential. If AOA Dx's lead test captured a meaningful portion of the over 200,000 new ovarian cancer cases diagnosed globally each year at a price point comparable to other advanced diagnostics (e.g., several thousand dollars per test), the revenue potential would support a valuation well into the hundreds of millions, with platform optionality pushing it higher. This represents a scenario, not a forecast, contingent on clinical and commercial execution.

Data Accuracy: YELLOW -- The core opportunity thesis is built on company-published performance data and platform claims, which require independent clinical validation. The growth scenarios are plausible extrapolations based on the stated technology platform and investor base.

Sources

PUBLIC

1. [StartupIntros] AOA Dx, Inc. | https://startupintros.com/orgs/aoa-dx-inc

2. [YouTube] Creating a New Path in Women's Health | Oriana Papin-Zoghbi | https://www.youtube.com/watch?v=coQF1_8G1ug

3. [Overlooked Podcast] Creating a New Path in Women's Health | Oriana Papin-Zoghbi | https://overlookedpod.com/episode/creating-a-new-path-in-womens-health-oriana-papin-zoghbi

4. [Crunchbase, 2026] AOA Dx - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/aoa-569f

5. [LongeVC, 2026] AOA Dx - Portfolio | https://longevc.com/portfolio

6. [Y Combinator] AOA Dx | https://www.ycombinator.com/companies/aoa-dx-inc

7. [Dealroom] AOA Dx | https://app.dealroom.co/companies/aoa

8. [AOA Dx] AOA Dx | https://aoadx.com

9. [CB Insights, 2026] AOA Dx Company Profile | https://www.cbinsights.com/company/aoa-dx

10. [Grand View Research] Liquid Biopsy Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

11. [Precedence Research] Women's Health Diagnostics Market | https://www.precedenceresearch.com/womens-health-diagnostics-market

12. [American Cancer Society] Survival Rates for Ovarian Cancer | https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html

13. [Rock Health] 2023 Year End Funding Report: Women's Health | https://rockhealth.com/insights/2023-year-end-funding-report-womens-health/

14. [Forbes, 2021] I had a baby while preparing for Y Combinator. | https://markets.businessinsider.com/news/stocks/y-combinator-startups-founder-stories-demo-day